Below is what's known on the subject. In a randomized clinical trial (RTOG 0521), the 4-year overall survival after RT+ADT was 89 percent without docetaxel and 93 percent with it. Not much of a difference and certainly not enough to justify the toxicity risk.
Adding docetaxel to ADT and radiation therapy for high-risk prostate cancerGETUG 12 (a French clinical trial) also had an arm that received both RT/ADT and chemo (docetaxel+estramustine). Progression-free survival was 62% with the chemo and 53% without it, but the difference was not statistically significant. There's another clinical trial from Spain (QRT SOGUG) that we haven't yet seen the results from.
While Dr. Lam is an excellent medical oncologist, I think the specialist you should be talking to is a radiation oncologist.
- Allen